Janssen Pharmaceuticals, a pharmaceutical company of Johnson & Johnson, has announced an expanded policy on improved accessibility of medicines in which the geographic scope of its earlier 2012 policy of waiving enforcement of patent rights for pediatric formulations of Darunavir, is expanded. This expansion includes many low and middle income countries including India, Pakistan and Sri Lanka. The company has further committed itself to providing technical expertise to Pediatric HIV Treatment Initiative (PHTI) on developing a fixed-dose combination of Darunavir boosted with ritonavir (DRV/r).